12040 115th Ave., NE
Kirkland, WA 98034
Office: (425) 823-0400
Fax: (425) 823-8508
Potential Promising Therapy for Parkinson's disease
Synuclere™ is our compound for the treatment of Parkinson's disease and is in late pre-clinical stage of development. Research for this project has been partially funded by The Michael J. Fox Foundation for Parkinson's Research LEAPS (Linked Efforts to Accelerate Parkinson's Solutions) award program.
Synuclere™ has been shown in vitro and in Parkinson's disease (i.e., Alpha-Synuclein) transgenic mice to prevent the formation and accumulation of Alpha-Synuclein deposits and aggregates believed to be important in the formation and/or progression of Parkinson's disease. In addition, Synuclere™ has been shown to cause a reduction and clearance of aggregated Alpha-Synuclein from brain of transgenic animals, leading to a marked improvement in motor dysfunction.
ProteoTech research has shown that Synuclere™ is well positioned to address a large and growing unmet need for people who suffer from Parkinson's disease and other forms of Lewy Body dementia.